Novartis' Tekturna, diuretic combo wins FDA approval

01/21/2008 | Wall Street Journal (free content), The

The FDA has granted Novartis AG approval to market a combination of its blood-pressure lowering drug Tekturna and the diuretic HCT in a single-tablet formulation, the company announced Monday. The combination drug proved more effective in lowering blood pressure than either component alone in clinical trials.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC